ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Gene Engineered Subunit Vaccine Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-19Y5864
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Gene Engineered Subunit Vaccine Market Insights Forecast to 2028
BUY CHAPTERS

Global Gene Engineered Subunit Vaccine Market Research Report 2025

Code: QYRE-Auto-19Y5864
Report
June 2025
Pages:102
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck
GSK
Tiantan
Pulike
Greffex Inc
CureVac
Yebio
Sanofi Pasteur SA.
Virbac
Pfizer Inc
Walvax Biotechnology
Kontec
Novavax Inc
Sanofi Pasteur
Bharat Biotech
GlaxoSmithKline PLC
Moderna, Inc

Gene Engineered Subunit Vaccine Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Gene Engineered Subunit Vaccine Market

Gene Engineered Subunit Vaccine Market

The global market for Gene Engineered Subunit Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gene Engineered Subunit Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Engineered Subunit Vaccine.
The Gene Engineered Subunit Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gene Engineered Subunit Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Engineered Subunit Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Gene Engineered Subunit Vaccine Market Report

Report Metric Details
Report Name Gene Engineered Subunit Vaccine Market
CAGR 5%
Segment by Type
  • Therapeutic Gene Engineered Subunit Vaccine
  • Preventative Gene Engineered Subunit Vaccine
Segment by Application
  • Human Use
  • Veterinary Use
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck, GSK, Tiantan, Pulike, Greffex, CureVac, Yebio, Sanofi Pasteur SA, Virbac, Pfizer Inc., Walvax Biotechnology, Kontec, Novavax, Sanofi Pasteur, Bharat Biotech, GlaxoSmithKline, Pfizer, Moderna
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Gene Engineered Subunit Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Gene Engineered Subunit Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Gene Engineered Subunit Vaccine Market report?

Ans: The main players in the Gene Engineered Subunit Vaccine Market are Merck, GSK, Tiantan, Pulike, Greffex, CureVac, Yebio, Sanofi Pasteur SA, Virbac, Pfizer Inc., Walvax Biotechnology, Kontec, Novavax, Sanofi Pasteur, Bharat Biotech, GlaxoSmithKline, Pfizer, Moderna

What are the Application segmentation covered in the Gene Engineered Subunit Vaccine Market report?

Ans: The Applications covered in the Gene Engineered Subunit Vaccine Market report are Human Use, Veterinary Use

What are the Type segmentation covered in the Gene Engineered Subunit Vaccine Market report?

Ans: The Types covered in the Gene Engineered Subunit Vaccine Market report are Therapeutic Gene Engineered Subunit Vaccine, Preventative Gene Engineered Subunit Vaccine

1 Gene Engineered Subunit Vaccine Market Overview
1.1 Product Definition
1.2 Gene Engineered Subunit Vaccine by Type
1.2.1 Global Gene Engineered Subunit Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Therapeutic Gene Engineered Subunit Vaccine
1.2.3 Preventative Gene Engineered Subunit Vaccine
1.3 Gene Engineered Subunit Vaccine by Application
1.3.1 Global Gene Engineered Subunit Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Human Use
1.3.3 Veterinary Use
1.4 Global Gene Engineered Subunit Vaccine Market Size Estimates and Forecasts
1.4.1 Global Gene Engineered Subunit Vaccine Revenue 2020-2031
1.4.2 Global Gene Engineered Subunit Vaccine Sales 2020-2031
1.4.3 Global Gene Engineered Subunit Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Gene Engineered Subunit Vaccine Market Competition by Manufacturers
2.1 Global Gene Engineered Subunit Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Gene Engineered Subunit Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Gene Engineered Subunit Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Gene Engineered Subunit Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Gene Engineered Subunit Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gene Engineered Subunit Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Gene Engineered Subunit Vaccine, Date of Enter into This Industry
2.8 Global Gene Engineered Subunit Vaccine Market Competitive Situation and Trends
2.8.1 Global Gene Engineered Subunit Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Gene Engineered Subunit Vaccine Players Market Share by Revenue
2.8.3 Global Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Gene Engineered Subunit Vaccine Market Scenario by Region
3.1 Global Gene Engineered Subunit Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Gene Engineered Subunit Vaccine Sales by Region: 2020-2031
3.2.1 Global Gene Engineered Subunit Vaccine Sales by Region: 2020-2025
3.2.2 Global Gene Engineered Subunit Vaccine Sales by Region: 2026-2031
3.3 Global Gene Engineered Subunit Vaccine Revenue by Region: 2020-2031
3.3.1 Global Gene Engineered Subunit Vaccine Revenue by Region: 2020-2025
3.3.2 Global Gene Engineered Subunit Vaccine Revenue by Region: 2026-2031
3.4 North America Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.4.1 North America Gene Engineered Subunit Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Gene Engineered Subunit Vaccine Sales by Country (2020-2031)
3.4.3 North America Gene Engineered Subunit Vaccine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.5.1 Europe Gene Engineered Subunit Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Gene Engineered Subunit Vaccine Sales by Country (2020-2031)
3.5.3 Europe Gene Engineered Subunit Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gene Engineered Subunit Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Gene Engineered Subunit Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Gene Engineered Subunit Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Gene Engineered Subunit Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.7.1 Latin America Gene Engineered Subunit Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Gene Engineered Subunit Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Gene Engineered Subunit Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gene Engineered Subunit Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Gene Engineered Subunit Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Gene Engineered Subunit Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Gene Engineered Subunit Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gene Engineered Subunit Vaccine Sales by Type (2020-2031)
4.1.1 Global Gene Engineered Subunit Vaccine Sales by Type (2020-2025)
4.1.2 Global Gene Engineered Subunit Vaccine Sales by Type (2026-2031)
4.1.3 Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Gene Engineered Subunit Vaccine Revenue by Type (2020-2031)
4.2.1 Global Gene Engineered Subunit Vaccine Revenue by Type (2020-2025)
4.2.2 Global Gene Engineered Subunit Vaccine Revenue by Type (2026-2031)
4.2.3 Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Gene Engineered Subunit Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Gene Engineered Subunit Vaccine Sales by Application (2020-2031)
5.1.1 Global Gene Engineered Subunit Vaccine Sales by Application (2020-2025)
5.1.2 Global Gene Engineered Subunit Vaccine Sales by Application (2026-2031)
5.1.3 Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Gene Engineered Subunit Vaccine Revenue by Application (2020-2031)
5.2.1 Global Gene Engineered Subunit Vaccine Revenue by Application (2020-2025)
5.2.2 Global Gene Engineered Subunit Vaccine Revenue by Application (2026-2031)
5.2.3 Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Gene Engineered Subunit Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Gene Engineered Subunit Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK Gene Engineered Subunit Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Tiantan
6.3.1 Tiantan Company Information
6.3.2 Tiantan Description and Business Overview
6.3.3 Tiantan Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Tiantan Gene Engineered Subunit Vaccine Product Portfolio
6.3.5 Tiantan Recent Developments/Updates
6.4 Pulike
6.4.1 Pulike Company Information
6.4.2 Pulike Description and Business Overview
6.4.3 Pulike Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pulike Gene Engineered Subunit Vaccine Product Portfolio
6.4.5 Pulike Recent Developments/Updates
6.5 Greffex
6.5.1 Greffex Company Information
6.5.2 Greffex Description and Business Overview
6.5.3 Greffex Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Greffex Gene Engineered Subunit Vaccine Product Portfolio
6.5.5 Greffex Recent Developments/Updates
6.6 CureVac
6.6.1 CureVac Company Information
6.6.2 CureVac Description and Business Overview
6.6.3 CureVac Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 CureVac Gene Engineered Subunit Vaccine Product Portfolio
6.6.5 CureVac Recent Developments/Updates
6.7 Yebio
6.7.1 Yebio Company Information
6.7.2 Yebio Description and Business Overview
6.7.3 Yebio Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Yebio Gene Engineered Subunit Vaccine Product Portfolio
6.7.5 Yebio Recent Developments/Updates
6.8 Sanofi Pasteur SA
6.8.1 Sanofi Pasteur SA Company Information
6.8.2 Sanofi Pasteur SA Description and Business Overview
6.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product Portfolio
6.8.5 Sanofi Pasteur SA Recent Developments/Updates
6.9 Virbac
6.9.1 Virbac Company Information
6.9.2 Virbac Description and Business Overview
6.9.3 Virbac Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Virbac Gene Engineered Subunit Vaccine Product Portfolio
6.9.5 Virbac Recent Developments/Updates
6.10 Pfizer Inc.
6.10.1 Pfizer Inc. Company Information
6.10.2 Pfizer Inc. Description and Business Overview
6.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Pfizer Inc. Gene Engineered Subunit Vaccine Product Portfolio
6.10.5 Pfizer Inc. Recent Developments/Updates
6.11 Walvax Biotechnology
6.11.1 Walvax Biotechnology Company Information
6.11.2 Walvax Biotechnology Description and Business Overview
6.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Walvax Biotechnology Gene Engineered Subunit Vaccine Product Portfolio
6.11.5 Walvax Biotechnology Recent Developments/Updates
6.12 Kontec
6.12.1 Kontec Company Information
6.12.2 Kontec Description and Business Overview
6.12.3 Kontec Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Kontec Gene Engineered Subunit Vaccine Product Portfolio
6.12.5 Kontec Recent Developments/Updates
6.13 Novavax
6.13.1 Novavax Company Information
6.13.2 Novavax Description and Business Overview
6.13.3 Novavax Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Novavax Gene Engineered Subunit Vaccine Product Portfolio
6.13.5 Novavax Recent Developments/Updates
6.14 Sanofi Pasteur
6.14.1 Sanofi Pasteur Company Information
6.14.2 Sanofi Pasteur Description and Business Overview
6.14.3 Sanofi Pasteur Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Sanofi Pasteur Gene Engineered Subunit Vaccine Product Portfolio
6.14.5 Sanofi Pasteur Recent Developments/Updates
6.15 Bharat Biotech
6.15.1 Bharat Biotech Company Information
6.15.2 Bharat Biotech Description and Business Overview
6.15.3 Bharat Biotech Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Bharat Biotech Gene Engineered Subunit Vaccine Product Portfolio
6.15.5 Bharat Biotech Recent Developments/Updates
6.16 GlaxoSmithKline
6.16.1 GlaxoSmithKline Company Information
6.16.2 GlaxoSmithKline Description and Business Overview
6.16.3 GlaxoSmithKline Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 GlaxoSmithKline Gene Engineered Subunit Vaccine Product Portfolio
6.16.5 GlaxoSmithKline Recent Developments/Updates
6.17 Pfizer
6.17.1 Pfizer Company Information
6.17.2 Pfizer Description and Business Overview
6.17.3 Pfizer Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Pfizer Gene Engineered Subunit Vaccine Product Portfolio
6.17.5 Pfizer Recent Developments/Updates
6.18 Moderna
6.18.1 Moderna Company Information
6.18.2 Moderna Description and Business Overview
6.18.3 Moderna Gene Engineered Subunit Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Moderna Gene Engineered Subunit Vaccine Product Portfolio
6.18.5 Moderna Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gene Engineered Subunit Vaccine Industry Chain Analysis
7.2 Gene Engineered Subunit Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gene Engineered Subunit Vaccine Production Mode & Process Analysis
7.4 Gene Engineered Subunit Vaccine Sales and Marketing
7.4.1 Gene Engineered Subunit Vaccine Sales Channels
7.4.2 Gene Engineered Subunit Vaccine Distributors
7.5 Gene Engineered Subunit Vaccine Customer Analysis
8 Gene Engineered Subunit Vaccine Market Dynamics
8.1 Gene Engineered Subunit Vaccine Industry Trends
8.2 Gene Engineered Subunit Vaccine Market Drivers
8.3 Gene Engineered Subunit Vaccine Market Challenges
8.4 Gene Engineered Subunit Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Merck
GSK
Tiantan
Pulike
Greffex Inc
CureVac
Yebio
Sanofi Pasteur SA.
Virbac
Pfizer Inc
Walvax Biotechnology
Kontec
Novavax Inc
Sanofi Pasteur
Bharat Biotech
GlaxoSmithKline PLC
Moderna, Inc
List of Tables
 Table 1. Global Gene Engineered Subunit Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Gene Engineered Subunit Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Gene Engineered Subunit Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Gene Engineered Subunit Vaccine Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global Gene Engineered Subunit Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Gene Engineered Subunit Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Gene Engineered Subunit Vaccine Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Gene Engineered Subunit Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Gene Engineered Subunit Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Gene Engineered Subunit Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Gene Engineered Subunit Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Gene Engineered Subunit Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Engineered Subunit Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Gene Engineered Subunit Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Gene Engineered Subunit Vaccine Sales by Region (2020-2025) & (K Dose)
 Table 18. Global Gene Engineered Subunit Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Gene Engineered Subunit Vaccine Sales by Region (2026-2031) & (K Dose)
 Table 20. Global Gene Engineered Subunit Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Gene Engineered Subunit Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Gene Engineered Subunit Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Gene Engineered Subunit Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Gene Engineered Subunit Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Gene Engineered Subunit Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Gene Engineered Subunit Vaccine Sales by Country (2020-2025) & (K Dose)
 Table 27. North America Gene Engineered Subunit Vaccine Sales by Country (2026-2031) & (K Dose)
 Table 28. North America Gene Engineered Subunit Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Gene Engineered Subunit Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Gene Engineered Subunit Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Gene Engineered Subunit Vaccine Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe Gene Engineered Subunit Vaccine Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe Gene Engineered Subunit Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Gene Engineered Subunit Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Gene Engineered Subunit Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Gene Engineered Subunit Vaccine Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific Gene Engineered Subunit Vaccine Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific Gene Engineered Subunit Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Gene Engineered Subunit Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Gene Engineered Subunit Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Gene Engineered Subunit Vaccine Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America Gene Engineered Subunit Vaccine Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America Gene Engineered Subunit Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Gene Engineered Subunit Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Gene Engineered Subunit Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Gene Engineered Subunit Vaccine Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa Gene Engineered Subunit Vaccine Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa Gene Engineered Subunit Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Gene Engineered Subunit Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Type (2020-2025)
 Table 51. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Type (2026-2031)
 Table 52. Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Gene Engineered Subunit Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Type (2020-2025)
 Table 59. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Type (2026-2031)
 Table 60. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Application (2020-2025)
 Table 61. Global Gene Engineered Subunit Vaccine Sales (K Dose) by Application (2026-2031)
 Table 62. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Gene Engineered Subunit Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Gene Engineered Subunit Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Application (2020-2025)
 Table 69. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Application (2026-2031)
 Table 70. Merck Company Information
 Table 71. Merck Description and Business Overview
 Table 72. Merck Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. Merck Gene Engineered Subunit Vaccine Product
 Table 74. Merck Recent Developments/Updates
 Table 75. GSK Company Information
 Table 76. GSK Description and Business Overview
 Table 77. GSK Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. GSK Gene Engineered Subunit Vaccine Product
 Table 79. GSK Recent Developments/Updates
 Table 80. Tiantan Company Information
 Table 81. Tiantan Description and Business Overview
 Table 82. Tiantan Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. Tiantan Gene Engineered Subunit Vaccine Product
 Table 84. Tiantan Recent Developments/Updates
 Table 85. Pulike Company Information
 Table 86. Pulike Description and Business Overview
 Table 87. Pulike Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. Pulike Gene Engineered Subunit Vaccine Product
 Table 89. Pulike Recent Developments/Updates
 Table 90. Greffex Company Information
 Table 91. Greffex Description and Business Overview
 Table 92. Greffex Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Greffex Gene Engineered Subunit Vaccine Product
 Table 94. Greffex Recent Developments/Updates
 Table 95. CureVac Company Information
 Table 96. CureVac Description and Business Overview
 Table 97. CureVac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. CureVac Gene Engineered Subunit Vaccine Product
 Table 99. CureVac Recent Developments/Updates
 Table 100. Yebio Company Information
 Table 101. Yebio Description and Business Overview
 Table 102. Yebio Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. Yebio Gene Engineered Subunit Vaccine Product
 Table 104. Yebio Recent Developments/Updates
 Table 105. Sanofi Pasteur SA Company Information
 Table 106. Sanofi Pasteur SA Description and Business Overview
 Table 107. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Sanofi Pasteur SA Gene Engineered Subunit Vaccine Product
 Table 109. Sanofi Pasteur SA Recent Developments/Updates
 Table 110. Virbac Company Information
 Table 111. Virbac Description and Business Overview
 Table 112. Virbac Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 113. Virbac Gene Engineered Subunit Vaccine Product
 Table 114. Virbac Recent Developments/Updates
 Table 115. Pfizer Inc. Company Information
 Table 116. Pfizer Inc. Description and Business Overview
 Table 117. Pfizer Inc. Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 118. Pfizer Inc. Gene Engineered Subunit Vaccine Product
 Table 119. Pfizer Inc. Recent Developments/Updates
 Table 120. Walvax Biotechnology Company Information
 Table 121. Walvax Biotechnology Description and Business Overview
 Table 122. Walvax Biotechnology Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 123. Walvax Biotechnology Gene Engineered Subunit Vaccine Product
 Table 124. Walvax Biotechnology Recent Developments/Updates
 Table 125. Kontec Company Information
 Table 126. Kontec Description and Business Overview
 Table 127. Kontec Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 128. Kontec Gene Engineered Subunit Vaccine Product
 Table 129. Kontec Recent Developments/Updates
 Table 130. Novavax Company Information
 Table 131. Novavax Description and Business Overview
 Table 132. Novavax Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 133. Novavax Gene Engineered Subunit Vaccine Product
 Table 134. Novavax Recent Developments/Updates
 Table 135. Sanofi Pasteur Company Information
 Table 136. Sanofi Pasteur Description and Business Overview
 Table 137. Sanofi Pasteur Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 138. Sanofi Pasteur Gene Engineered Subunit Vaccine Product
 Table 139. Sanofi Pasteur Recent Developments/Updates
 Table 140. Bharat Biotech Company Information
 Table 141. Bharat Biotech Description and Business Overview
 Table 142. Bharat Biotech Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 143. Bharat Biotech Gene Engineered Subunit Vaccine Product
 Table 144. Bharat Biotech Recent Developments/Updates
 Table 145. GlaxoSmithKline Company Information
 Table 146. GlaxoSmithKline Description and Business Overview
 Table 147. GlaxoSmithKline Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 148. GlaxoSmithKline Gene Engineered Subunit Vaccine Product
 Table 149. GlaxoSmithKline Recent Developments/Updates
 Table 150. Pfizer Company Information
 Table 151. Pfizer Description and Business Overview
 Table 152. Pfizer Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 153. Pfizer Gene Engineered Subunit Vaccine Product
 Table 154. Pfizer Recent Developments/Updates
 Table 155. Moderna Company Information
 Table 156. Moderna Description and Business Overview
 Table 157. Moderna Gene Engineered Subunit Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 158. Moderna Gene Engineered Subunit Vaccine Product
 Table 159. Moderna Recent Developments/Updates
 Table 160. Key Raw Materials Lists
 Table 161. Raw Materials Key Suppliers Lists
 Table 162. Gene Engineered Subunit Vaccine Distributors List
 Table 163. Gene Engineered Subunit Vaccine Customers List
 Table 164. Gene Engineered Subunit Vaccine Market Trends
 Table 165. Gene Engineered Subunit Vaccine Market Drivers
 Table 166. Gene Engineered Subunit Vaccine Market Challenges
 Table 167. Gene Engineered Subunit Vaccine Market Restraints
 Table 168. Research Programs/Design for This Report
 Table 169. Key Data Information from Secondary Sources
 Table 170. Key Data Information from Primary Sources
 Table 171. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Gene Engineered Subunit Vaccine
 Figure 2. Global Gene Engineered Subunit Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Gene Engineered Subunit Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Therapeutic Gene Engineered Subunit Vaccine Product Picture
 Figure 5. Preventative Gene Engineered Subunit Vaccine Product Picture
 Figure 6. Global Gene Engineered Subunit Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Gene Engineered Subunit Vaccine Market Share by Application: 2024 & 2031
 Figure 8. Human Use
 Figure 9. Veterinary Use
 Figure 10. Global Gene Engineered Subunit Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Gene Engineered Subunit Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Gene Engineered Subunit Vaccine Sales (2020-2031) & (K Dose)
 Figure 13. Global Gene Engineered Subunit Vaccine Average Price (US$/Dose) & (2020-2031)
 Figure 14. Gene Engineered Subunit Vaccine Report Years Considered
 Figure 15. Gene Engineered Subunit Vaccine Sales Share by Manufacturers in 2024
 Figure 16. Global Gene Engineered Subunit Vaccine Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Gene Engineered Subunit Vaccine Players: Market Share by Revenue in Gene Engineered Subunit Vaccine in 2024
 Figure 18. Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Gene Engineered Subunit Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Gene Engineered Subunit Vaccine Sales Market Share by Country (2020-2031)
 Figure 21. North America Gene Engineered Subunit Vaccine Revenue Market Share by Country (2020-2031)
 Figure 22. U.S. Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Gene Engineered Subunit Vaccine Sales Market Share by Country (2020-2031)
 Figure 25. Europe Gene Engineered Subunit Vaccine Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Gene Engineered Subunit Vaccine Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Gene Engineered Subunit Vaccine Revenue Market Share by Region (2020-2031)
 Figure 33. China Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Taiwan Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Philippines Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Gene Engineered Subunit Vaccine Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Gene Engineered Subunit Vaccine Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Gene Engineered Subunit Vaccine Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Gene Engineered Subunit Vaccine Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Gene Engineered Subunit Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Gene Engineered Subunit Vaccine by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Gene Engineered Subunit Vaccine by Type (2020-2031)
 Figure 55. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Gene Engineered Subunit Vaccine by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Gene Engineered Subunit Vaccine by Application (2020-2031)
 Figure 58. Global Gene Engineered Subunit Vaccine Price (US$/Dose) by Application (2020-2031)
 Figure 59. Gene Engineered Subunit Vaccine Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Genetic Vaccine Market Insights Forecast to 2030
Global Genetically Engineered Vaccines for Poultry Market Research Report 2024
Global Poultry Genetic Engineering Vaccine Market Research Report 2024
Genetically Engineered Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Protein Vaccine Market Insights Forecast to 2030
HPV Genetically Engineered Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gene Deletion Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Livestock Genetic Engineering Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Genetically Engineered Vaccines for Livestock Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global DNA Vaccination Market Research Report 2024
Human Genetically Engineered Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gene Deleted Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Genetically Engineered Vector Vaccine Market Research Report 2024
Recombinant DNA Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global DNA Vaccines Market Insights Forecast to 2030
mRNA Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Therapeutic Cancer Vaccines Market Research Report 2024
Recombinant Protein Therapeutics Market
Global Recombinant Influenza Vaccine Market Research Report 2024
Global Engineered Bacterial Cell Protein Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions